Clinical trial readouts. What's coming, what it means.
Upcoming Phase 3 readouts, FDA decisions, and regulatory milestones in the peptide and GLP-1 space. What each means for the evidence base, the regulatory landscape, and patient access.
- July 2026·FDA·Regulatory
PCAC advisory committee hearing — 14 peptides on Category 2 list
Indication: Compounding eligibility review
The hearing that converts February 2026's HHS proposed removal into an actual FDA ruling. Whatever comes out determines legal compounding access for BPC-157, GHK-Cu, CJC-1295, MOTS-c, thymosin-alpha-1, and 9 others.
- H2 2026·Eli Lilly·Phase 3
TRIUMPH-1 (retatrutide) — Retatrutide
Indication: Chronic weight management
The efficacy readout that determines whether retatrutide extends the weight-loss ceiling past tirzepatide's ~20% floor. Phase 2 suggested 24%+; Phase 3 durability is the question.
- H2 2026·Novo Nordisk·Phase 3
REDEFINE-2 — CagriSema (cagrilintide + semaglutide)
Indication: Type 2 diabetes + obesity
Extending the REDEFINE-1 weight-management win into the T2D population. If positive, broadens the CagriSema label considerably.
- Late 2026·Eli Lilly·Regulatory
FDA decision on orforglipron — Orforglipron (Foundayo)
Indication: Chronic weight management
First oral small-molecule GLP-1 approval decision. Binary event with enormous supply-chain implications — oral small molecules aren't constrained by peptide manufacturing.
- 2027·Eli Lilly·CV outcomes
SURPASS-CVOT — Tirzepatide
Indication: Cardiovascular outcomes in T2D
Tirzepatide's answer to SELECT (semaglutide's MACE-reduction trial). A positive CVOT makes tirzepatide stronger on the CV-risk-reduction dimension than semaglutide has been.
- 2027·Novo Nordisk·Phase 3
evoke / evoke+ — Semaglutide
Indication: Alzheimer's disease
If positive, rewrites the semaglutide story beyond metabolic disease entirely. Null result doesn't hurt the obesity franchise but closes a high-expectation research frontier.
- 2027·Boehringer Ingelheim / Zealand Pharma·Phase 3
SYNCHRONIZE (survodutide) — Survodutide
Indication: Chronic weight management
Second dual GLP-1/glucagon agonist in Phase 3 after retatrutide. Readout establishes whether the class is tolerable at scale or whether retatrutide is a singleton.
- 2027-2028·Novo Nordisk·Phase 3
Amycretin Phase 3 entry + readouts — Amycretin
Indication: Chronic weight management
Single-molecule amylin/GLP-1 agonist aims to deliver CagriSema-class efficacy without the fixed-dose combination. If it works, it's the preferred single-molecule path for Novo going forward.